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Abstract 
Immunoinhibitory cell receptors that can induce a state of T cell exhaustion upon 
exposure to tumor antigen include Programmed Cell Death-1 (PD1). Although much 
research has been conducted on PD1, global miRNA regulation of PD1 in a cancer model 
has not been investigated. We hypothesized that miRNAs exist that can silence PD1 in 
vitro and revert symptoms of T cell exhaustion. Eleven miRNAs were discovered with 
altered expression between PD1+ and PD1- CD4+ T cells from melanoma-bearing mice. 
miR-28 and miR-107 mimics were shown to bind to and silence the 3’UTR of PD1, and 
miR-28, miR-150 and miR-107 inhibitors increased PD1 expression. Furthermore, no 
changes were observed in anti-CD3e induced proliferation, while miR-28 and miR-107 
mimic transfection significantly reduced activation-induced apoptosis. This study is the 
first of its kind to discover global miRNA profiles in PD1+ T cells, providing novel 
targets for potential use as prognostic and therapeutic markers in melanoma. 
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Chapter 1  
1 Introduction 
1.1 Melanoma and epidemiology 
There are three types of skin cancer, which are named from the cells they emerge from: 
non-melanoma skin cancers such as squamous cell carcinoma and basal cell carcinoma, 
and the deadliest kind known as melanoma [1]. Melanoma begins in melanocytes, the 
pigment producing cells in the skin, and is primarily caused through unrepaired DNA 
damage from ultraviolet radiation [1]. Melanocytes make up about 5-10% of all skin cells 
and, in humans, are distributed as single cells within the basal layer of the epidermis, 
while mouse melanocytes are found in the dermis in hair follicles [2]. Each melanocyte is 
surrounded by approximately 5 keratinocytes, but maintain contact with up to 40 
surrounding keratinocytes through dendritic extensions, thus forming an epidermal 
melanin unit [3]. Upon exposure to sunlight, a keratinocyte signals to its connecting 
melanocyte to synthesize melanin in vesicles known as melanosomes. These 
melanosomes are transported through the dendritic connections to deposit melanin in the 
keratinocytes, which protects by cells from UV radiation by absorbing UV photons and 
removing highly reactive oxygen radicals [4]. With enough UV radiation, mutations can 
occur that cause melanocytes to grow out of control into a tumor. However, since 
melanoma can occur in areas of that body that receive little to no sunlight, it is believed 
that a combination of environmental and genetic factors lead to the development of 
melanoma. 
In 2014, it is estimated that there was approximately 6,500 new melanoma cases 
and 1,050 melanoma-related deaths in Canada, representing 3% of new cancer cases and 
1.4% of cancer deaths [1]. Over the 5 year span from 2006-2010, approximately 8% of 
new cancer cases affected 15-29 year old and 6% of new cases in 30-49 year olds were 
melanoma diagnoses [1]. Luckily, the five-year relative survival rate for melanoma is 
85% and 92% in men and women, respectively [1]. However, melanoma and non-
melanoma skin cancer is the most common cancer in Canada, which accounts for nearly 
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the same number of new cases as lung, breast, colorectal and prostate cancer combined, 
thus demonstrating a need to conduct further research on all aspects of melanoma 
treatment, diagnoses and prevention [1]. 
 The model used in this study was a murine model of metastatic melanoma 
developed by subcutaneous injection of B16F10 cells. This cell line was generated in 
1975 by intravenously injecting C57BL/6 mice with B16 cells, isolating pulmonary 
melanoma nodules and culturing the cells before injection into a new C57BL/6 mice [5]. 
This process was repeated 10 times to generate the metastatic B16F10 cell line that has 
been shown to have increased metastatic ability over parent B16F1 cells [6]. 
 
1.1.1 Current treatment strategies 
Treatment for melanoma is quite difficult and its history demonstrates a lack of advances 
until the past few years. Although early-stage melanoma is easily cured, more advanced 
stages are quite refractory to treatment. Before the approval of Ipilimumab in 2011, no 
single drug or synergistic treatment demonstrated a significant increase in the overall 
survival rate of metastatic melanoma [7]. The first drug approved by the Food and Drug 
Administration (FDA) in 1975 for treatment of advanced melanoma was Dacarbazine, 
however the overall survival compared to placebo treatment was not significantly 
improved [8]. In 1995 interferon-α2b became the first FDA approved immunotherapeutic 
agent against stage IIB/III melanoma [9] and in 1998, interleukin-2 (IL-2) became a 
second exogenous cytokine treatment for antitumor activity in metastatic melanoma [10]. 
However, use of these agents resulted in no significant increase in overall survival even 
though higher response rates were observed [11]. Over time it was discovered that 
mutations in the V-RAF murine sarcoma viral oncogene homolog B (BRAF) acted as a 
proto-oncogene in almost 50% of cutaneous melanomas, with the majority, almost 90%, 
occurring at codon 600 [12]. In 2011 and 2013, the FDA approved Vemurafenib and 
Dabrafenib, respectively, small-molecule inhibitors of V600E and V600K mutations for 
treatment of V600-mutated melanoma [13]. Unfortunately resistance develops in many 
patients after 6 months, demonstrating the need for newer therapies [14]. Since BRAF 
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works by phosphorylating MEK1 and MEK2 in the MAPK/ERK pathway [15], a small-
molecule inhibitor of MEK1 and MEK2, Trametinib, was tested and approved by the 
FDA in May 2013 for the treatment of BRAF V600E and V600K [16]. Since January 
2014, the FDA has granted accelerated approval of a combination regime of Dabrafenib 
and Trametinib, which has published immature data that suggests that the resistance 
achieved through BRAF inhibition monotherapy may be curbed with the addition of a 
MEK inhibitor [17]. Other targeted therapies that have been approved by the FDA for 
other cancers and have recently been studied in melanoma involve tyrosine kinase (c-kit 
and bcr-abl) and angiogenesis (VEGF) inhibitors, however the results are not as 
promising as BRAF/MEK inhibitors or upcoming immunotherapies [18, 19]. 
Currently, although localized melanoma and regional lymph node resection is the 
standard of care, targeting the immune system provides an indirect method to control 
cancer cell growth by potentiating ongoing and inefficient antitumor immune responses 
to break tolerance [20]. Since the approval of an anti-CTLA4 antibody in 2011 there has 
been a surge of interest in moving the focus of cancer research toward removing 
intratumoral immune suppression [20, 21].  This suppression includes the activation of 
inhibitory receptors such as CTLA4, PD1, TIM3 and BTLA on T cells that triggers an 
immune checkpoint resulting in inhibition of T cells directed against cancer antigens, 
thus preventing the immune system from combating the cancer [22]. This phenomenon 
has loosely been termed, T cell exhaustion, since these inhibitory receptors bind B7 
molecules on antigen presenting cells preventing the activation of the CD28 co-
stimulatory signal or they may bind various ligands on tumor cells creating a state of T 
cell anergy. 
 
1.2 T cell exhaustion 
T cell exhaustion is when T cells, in response to antigen stimulation, fail to proliferate 
and exert effector functions such as cytotoxicity and cytokine secretion. Exhausted T 
cells were initially observed in chronic lymphocytic choriomeningitis virus (LCMV) 
infection in mice and characterized by sustained expression of programmed cell death-1 
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(PD1) [23, 24]. Blockade of the PD1/PD-L1 interaction resulted in reduced spontaneous 
apoptosis, enhanced expansion and improved cytokine secretion of the exhausted T cells 
[23, 24]. T cell exhaustion also occurs in cancer; PD1 expression is associated with CD8+ 
T cells in solid tumors and on antigen specific tumor-infiltrating CD8+ T cells [25-27]. 
Similar to the LCMV model, blockade of PD1/PD-L1 interaction in both humans and 
mice resulted in enhanced cytolytic activity of tumor-associated antigen (TAA)-specific 
CD8+ T cells and cytokine production of TAA-specific T helper cells when interacting 
directly with the tumor [26]. However, it is important to note that reversal of exhausted T 
cells does not always result from blockade of the PD1/PD-L1 interaction [27, 28]. Small 
interfering RNA (siRNA)-mediated knockdown of PD1 in T cells has shown to enhance 
their functions [29, 30], while in other cases siRNA-mediated PD1 knockdown of T cells 
did not affect their functions [28]. This indicates that other mechanisms and pathways are 
likely involved in T cell exhaustion. 
 One pathway that may also be involved in T cell exhaustion is the T-cell 
immunoglobulin and mucin-domain-containing molecule 3 (TIM3) negative regulatory 
pathway. CD4+ and CD8+ tumor infiltrating lymphocytes (TILs) in mice bearing the solid 
tumors for colon adenocarcinoma (CT-26), melanoma (B16) and breast cancer (4T1) 
coexpress TIM3 and PD1 [31]. More importantly, all TIM3+ TILs co-express PD1 in 
these 3 cancer models [31] and TIM3+/PD1+ CD8+ T-cells are more dysfunctional then 
TIM3-/PD1+ and TIM3-/PD1- CD8+ T cells as can be seen by a failure to proliferate and 
produce IL-2, TNFα, and IFNγ [31-33]. Targeting both pathways with anti-TIM3 [31, 
32]/TIM3 fusion protein [33] and anti-PD-L1 antibodies resulted in reversed tumor-
induced T cell exhaustion in vitro [32], reduced tumor growth in vivo [31] and reduced 
tumor burden and superior survival advantage in vivo [33] in both solid and non-solid 
cancers; colon adenocarcinoma [31], melanoma [32] and acute myeloid leukemia [33]. As 
well, the reduction of TIM3+PD1- cells was associated with an increased frequency of 
TIM3-PD1+ cells, thus, the combinational effect of anti-TIM3 and anti-PD1 in 
suppressing melanoma and colon adenocarcinoma growth may lead to the maintenance of 
TIM3-/PD1- T cells [34]. Therefore, combined antibody blockade of the PD1/PD-L1 and 
TIM3 in cancer has proven to be beneficial in reducing tumor growth and T cell 
exhaustion. 
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 A third pathway that may be involved in T cell exhaustion is the B and T 
lymphocyte attenuator (BTLA) negative regulatory pathway. BTLA+/PD1+/TIM3- and 
BTLA+PD1+TIM3+ NY-ESO-1–specific CD8+ T cells represent two dysfunctional T-cell 
populations, determined by decreased IL-2, TNF, and IFNγ cytokine production over 
BTLA-/PD1-/TIM3- and BTLA-/PD1+/TIM3- NY-ESO-1–specific CD8+ T cells [35]. 
Thus, BTLA+/PD1+/TIM3+ TILs represent the most exhausted TILs in advanced 
melanoma. The triple antibody blockade of BTLA, PD1 and TIM3 increased the 
proliferative capacity and the frequency of cytokine producing NY-ESO-1–specific CD8+ 
T cells compared to single and double blockades [35]. Taken together with the fact that 
naive T-cells are single or double positive for BTLA and TIM3, and NY-ESO-1+, Melan-
A+ and Mage-A10+ effector cells interact via larger numbers of inhibitory receptors [22], 
combinational blockade of these multiple inhibitory receptors seems to be the most 
efficient method to revert T cell exhaustion, stimulate naïve T cell maturity and promote 
anti-cancer immunity. So far, Fourcade J et al [32, 35] have found success with their 
studies on this combinational blockade in advanced melanoma in vitro; however, no one 
has attempted to observe the effects of RNA interference in a synergistic therapy against 
the PD1, TIM3 and BTLA pathways. 
 
1.2.1 Inhibitory cell receptors linked to T cell exhaustion 
PD1 is a type I transmembrane receptor and a member of the immunoglobin superfamily 
[36]. As well, PD1 is a member of the CD28 family of T-cell regulators and is expressed 
on the surface of T-cells, B-cells, macrophages and dendritic cells (DCs) [37-40]. PD1 
expression is induced upon T cell activation and upon PD-L1 and PD-L2 binding [41]. 
Receptors such as PD1 function by recruiting tyrosine phosphatases, including SHP-1, 
SHP-2 and SHIP, which are responsible for altering various B and T cell responses [38-
40]. Interaction between PD1 and its ligands PD-L1/PD-L2 are known to inhibit 
activation of immune responses by inducing T-lymphocyte anergy and apoptosis [42-45]. 
PD-L1 is expressed on resting B cells, T cells, macrophages and DCs [37]. The 
expression of PD-L1 is further up-regulated on these cells by various stimulation 
including anti-IgM, anti-CD40 and LPS for B cells; anti-CD3 for T cells; anti-CD40, 
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LPS, IFNy and granulocyte macrophage colony stimulating factor (GM-CSF) for 
macrophages; and anti-CD40, IFNy, GM-CSF, IL-4 and IL-12 for DCs [37]. On the other 
hand, PD-L2 is rarely expressed on resting cells and hardly induced on B cells and T cells 
[37]. PD-L2 can be induced on macrophages with IFNy and IL-4, and induced on DCs 
with anti-CD40, IFNy, GM-CSF, IL-4 and IL-12 [37]. IL-4 induces PD-L2 more strongly 
than IFNy, while IFNy induces PD-L1 more strongly than IL-4 on macrophages, 
suggesting that T-helper type 1 and type 2 responses mobilize PD-L1 and PD-L2 
differentially [46]. 
TIM3 belongs to the TIM family of molecules that in mice contains 8 members 
(TIM-1-8) and in humans contains 3 members (TIM-1,3,4) [47]. TIM3 is a novel 
transmembrane protein that is expressed on Th1 cells, cytotoxic CD8+ T cells, regulatory 
T cells, DCs, macrophages, monocytes, microglia and natural killer (NK) cells in mice 
and humans [48-56]. TIM3 was first found to be involved in the regulation of Th1 cell-
mediated immunity [48-50]. The interaction of TIM3 with its ligand galectin-9 dampens 
the response of both IFNγ producing CD4+ Th1 and CD8+ effector T cells, inducing cell 
death; in vivo blockade of this interaction results in exacerbated autoimmunity and 
abrogation of tolerance in experimental models, thus establishing TIM3 as a negative 
regulatory molecule of the adaptive immune system [48-52]. As well, TIM3 is able to 
suppress the nucleic acid-mediated innate immune system through interaction with 
HMGB1; preventing nucleic acid recruitment into DCs, which is important for antitumor 
immunogenicity in tumor microenvironments that release nucleic acids from dying tumor 
cells [53]. 
BTLA is an immunoglobulin domain-containing glycoprotein with two 
immunoreceptor tyrosine-based inhibitory motifs, is a third inhibitory molecule of 
lymphocytes that associates with SHP-1 and SHP-2 [57]. Depending on the BTLA allele, 
BTLA is known to be expressed by CD4+ Th1 cells, CD8+ T cells, B cells, macrophages, 
DCs, and NK cells [22, 35, 57-59]. BTLA inhibits T cell proliferation and cytokine 
production in vitro and plays a critical role in the induction of peripheral T-cell tolerance 
in vivo [57, 58]. In addition, BTLA mediates the negative regulation of CD8+ T-cell 
homeostasis and proliferation in vivo [59].  
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1.2.2 Clinical immunotherapies 
It is widely believed that blocking these negative regulatory molecules in cancer may 
attenuate tumor growth. Ipilimumab, a human monoclonal antibody against CTLA4, was 
approved by the FDA in March 2011 to be used on late stage melanoma [60, 61]. Studies 
on anti-PD1 antibodies (Nivolumab, Lambrolizumab and Pidilizumab) in various cancers 
including melanoma have entered stage 2-3 trials since late 2008 [60, 61]. Currently, no 
clinical studies are currently being conducted on TIM3 or BTLA antibodies against any 
cancer. Interestingly, some immunotherapies are being tested that block the PD1 ligand 
on the tumor cell, which has the benefit of potentiating the antitumor response at a tumor-
specific level [61]. Ultimately, research on blockade of the PD1/PD-L1 axis holds much 
promise, with greater response rates and lower toxicity due to their tumor-specific mode 
of activation, rather than generalized suppression of T cell inhibition [62]. A review on 
the 3 anti-PD1 and 4 anti-PD-L1 antibodies currently in clinical trials shows encouraging 
responses rates between 20%-50% that have continued responses after treatment and 
transient low-grade immune-related adverse effects [63]. 
 
1.3 Epigenetics 
Epigenetics can be defined as regulatory changes that modulate gene expression without 
changing the DNA sequence itself [64]. Modulation can occur by altering chromatin 
structure through DNA methylation or histone modification, or further downstream by 
regulating messenger RNA (mRNA) through non-coding RNAs such as microRNAs 
(miRNAs) [64, 65]. The beautiful aspect between the concept of epigenetics and genetics 
is that the former may be therapeutically intervened with greater ease [64]. Currently, a 
few therapies that affect DNA methylation and histone modification have been approved 
by the FDA: DNA methyltransferase (DNMT) inhibitors such as Decitabine and Vidaza, 
and histone deacetylase (HDAC) inhibitors such as Vorinostat and Romidepsin [66]. 
Although these drugs have been approved for acute leukemia and cutaneous T cell 
lymphoma [66], recent research has found convincing evidence for the role of epigenetics 
in future treatments of melanoma such as using histone deacetylase inhibitors and IL-2 
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[67]. Although miRNAs currently may not have as bold of a therapeutic approach as 
DNMT or HDAC inhibitors, the possibility exists and also extends to diagnostic and 
prognostic markers. 
 
1.4 RNA interference and microRNAs 
One potential mechanism by which PD1, TIM3 and BTLA synthesis can be modulated is 
by the induction of miRNAs. miRNAs are short (approximately 22 nucleotides) RNAs 
that regulate gene expression by base pairing with the 3’ untranslated regions (UTR) of 
mRNAs resulting in the translational inhibition or mRNA degradation [68]. Lin-4 was the 
first miRNA discovered in 1993, in the orgasm caenorhabditis elegans [69, 70] and five 
years later it was reported that exogenous double stranded RNA can silence genes 
through a mechanism termed RNA interference (RNAi) [71]. In 1999, the concept of 
RNAi was further understood when silencing in plants was correlated to small RNAs that 
match the sequence of the silenced transcript [72]. By 2001, two categories of small 
RNAs were classified under an RNAi role: miRNAs and siRNAs. miRNAs are known as 
regulators of endogenous genes and are expressed endogenously, while siRNAs protect 
our genome by reacting to foreign or invasive nucleic acids and are primarily exogenous 
in origin [73]. miRNAs do not have perfect complementarity when in the double stranded 
stem loop or to the mRNA targets, which allows one miRNA to bind several mRNA 
transcripts. siRNAs are perfectly complementary in their double stranded form and to 
their single target mRNA, thus resulting in mRNA degradation [74]. Although in rare 
cases siRNA that are perfectly matched may not utilize endonuclease activity to degrade 
mRNA, but rather silence in a way similar to miRNAs [74]. 
Now it is believed that over 1000 miRNAs exist in humans that regulate over 30% 
of our genome [75]. miRNAs originate from miRNA genes or introns of protein coding 
genes and are termed pri-miRNAs upon transcription by RNA polymerase II, resulting in 
capped and polyadenylated transcripts [76].  Pri-miRNAs have a stem loop shape and are 
processed by an enzyme Drosha, which is an endoribonuclease that cleaves 11 bp from 
the bottom of the stem leaving a 22 bp stem loop known as pre-miRNA [68]. From here, 
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Exportin-5 transports the pre-miRNA into the cytoplasm for further processing by Dicer 
[76]. Dicer cleaves the terminal loop which generates a double stranded RNA that is 
approximately 22 base pairs in length and has 3’ overhangs that are two nucleotides in 
length [76]. The last step involves separation of the two strands so that one gets 
incorporated in the RNA-induced silencing complex (RISC) [77]. The miRNA loaded 
RISC complex is then directed towards the 3’ UTR of target mRNAs, thus inducing 
repression of protein expression through mRNA degradation or translational inhibition 
[77]. 
  
1.5 miRNAs reported in melanoma 
Over the years, many miRNAs have been linked to melanoma development as either 
oncogenic or tumor suppressive miRNAs. miR-195, mir-221, miR-222, miR-193b, miR-
15b, miR-199a-5p, miR-424, miR-432-5p and the miR-let-7 family act as oncogenic 
miRNAs [65, 78-83], while miR-205, miR-26a, miR-34a, miR-125b, miR-18b, miR-573 
act as tumor suppressive miRNAs [84-89]. Many other miRNAs have been linked to 
melanoma, but this list demonstrates the potential for miRNAs to use be used clinically 
for detection, progression, prognosis, and therapy [90]. Although miRNAs such as miR-
155 and miR-150 are found upregulated in blood samples of patients suffering from 
chronic lymphocyte leukemia, it is unknown whether these changes are a result of the 
tumor or immune cells [91]. This highlights the importance of looking at specific tissue 
and cell types to understanding altered miRNA expression and its suitability for 
prognostic or therapeutic markers. As well, some miRNAs may be oncogenic or tumor 
suppressive depending on the cancer, such as miR-155 [92, 93], further demonstrating the 
need to understand miRNA regulation in specific diseases and cell types. 
 
1.5.1 Prognostic potential 
Although much work still needs to be done on prognostic markers in melanoma, 
summaries can be seen that highlight miRNAs miR-150, miR-342-3p, miR-455-3p, miR-
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145, miR-155, and miR-497 as predictors of long-term survival of metastatic melanoma 
[94]. Another study looked at lymph node metastasis and discovered that miR-191 was 
under-expressed and miR-193b was over-expressed in patients with poor melanoma-
specific survival [95]. Other studies do exist that have found correlations between 
additional miRNAs and how they may affect clinical outcome, thus demonstrating the 
need for more research to determine which miRNAs have the best clinical impact 
towards long term survival [84, 96, 97]. 
 
1.5.2 Therapeutic potential 
With the discovery of aberrant miRNA signatures in various diseases states, the idea of 
using antagomirs or miRNA mimics to restore miRNA function has become an intriguing 
therapeutic concept [98]. Various in vitro and in vivo studies have shown that use of 
miRNA mimics and antagomirs to miR-221, miR-222, miR-182, miR34a, miR-16 and 
miR-203 may prove beneficial in the treatment of advanced melanoma [79, 99-101]. 
Some issues that arise with the use of miRNA as a direct therapy involves targeted 
delivery methods, off-target miRNA binding effects and miRNA half-life. Although these 
issues may prevent the progression of miRNA as direct therapies, the possibility 
definitely exists that miRNAs can be used to predict response to various therapies. For 
example, Kheirelseif et al. used a microarray to identify a group of miRNAs as predictors 
of response to neoadjuvant chemoradiation therapy [102]. Currently, the expression of 
PD-L1 using immunohistochemistry (IHC) is used as a predictive biomarker for PD1/PD-
L1 therapy [63], however no miRNA biomarkers have been reported. By discovering 
miRNA biomarkers for use with IHC that can accurately predict therapy response, we can 
reduce the cost of cancer treatment by increasing objective response rates and minimizing 
the number of cancer patients that need multiple treatments. 
 
11 
 
 
 
1.6 microRNAs in T cell exhaustion 
Overall, little experimental research has been conducted on PD1, TIM3 and BTLA 
synergistically in cancer [31-33, 35], and no experimental research has been done to 
observe the effects of miRNAs on PD1, TIM3 and BTLA in melanoma and T cell 
exhaustion. Therefore, this study will provide valuable epigenetic data on the 
immunoinhibitory target, PD1, which supports the use of miRNAs as prognostic markers 
and therapeutic molecules to confer T cell immunity against melanoma. 
 
1.7 Rationale 
Currently, the immunotherapy using Ipilimumab is recommended at 4 cycles of 3 mg/kg 
per dose given every 3 weeks, which costs approximately $120,000 [103]. This large cost 
is a major hurdle for the use of new immunotherapies. It may inhibit the use of new 
therapies that seek to combine antibodies against the PD1 and CTLA4 pathway that are 
currently in clinical trials [63], as well, as any other combination of immunotherapy and 
cancer targeting antibody. By understanding altered miRNA expression in PD1+ T cells I 
hope to, for the first time, discover miRNAs that may target PD1 and have potential to be 
used as a synergistic therapy against multiple immunoinhibitory receptors. 
 
1.8 Hypothesis 
I hypothesize that miRNAs exist that can silence PD1 and potentially other inhibitory 
immunoreceptors such as TIM3 and BTLA. As well, that miRNA mimics in vitro can act 
therapeutically to revert symptoms of T cell exhaustion. 
 
 
12 
 
 
 
1.9 Specific aims 
The following 4 specific aims were chosen to test my hypothesis: 
1. To discover altered miRNA expression between PD1+ and PD1- T cells in 
melanoma-bearing mice 
2. To determine the PD1 silencing ability of candidate miRNAs using miRNA 
mimics and inhibitors 
3. To discover if the silencing candidate miRNAs affect CD4+ T cell proliferation 
and apoptosis in vitro. 
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Chapter 2  
2 Materials and methods 
2.1 B16F10 cell culture 
To investigate the miRNA regulation of PD1 in T cells in the context of melanoma, 
B16F10 mouse melanoma cells were used. B16F10 cells were obtained from ATCC 
(Manassas, VA). Cells were cultured using DMEM medium (Gibco, Life Technologies, 
Burlington, ON) made complete with 10% fetal bovine serum (FBS; Gibco), 100 
units/mL of penicillin (Gibco) and 100 µg/mL of streptomycin (Gibco) at 37 °C in 5% 
CO2. B16F10 cells were cultured and passaged in tissue culture flasks for at least 4 
passages, and were grown to approximately 80% confluency before each experiment was 
performed. 
 
2.2 Melanoma mouse model 
8-10 week old C57BL/6 mice (Charles River Canada, Saint-Constant, Canada) were used 
to generate a melanoma mouse model. Animals were housed under conventional 
conditions at the Animal Care Facility, Western University, and were cared for in 
accordance with the guidelines established by the Canadian Council on Animal Care. 
Tumors were generated on the backs of each mouse through subcutaneous injection of 
4x105 B16F10 cells in phosphate buffered saline (PBS; Gibco). Tumors were allowed to 
grow for 16 days or until reaching a size of 2,000 mm3. Mice were monitored daily and 
sacrificed using CO2 in accordance with the guidelines established by the Canadian 
Council on Animal Care. 
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2.3 Lymphocyte isolation 
2.3.1 Lymphocyte isolation from lymph nodes 
Lymph nodes were obtained from wild-type (WT) and tumor-bearing mice. Single cell 
suspensions were generated by pressing lymph nodes through a 40 µm Falcon Cell 
Strainer (VWR, Mississauga, ON) into RPMI 1640 medium (Gibco), and cells were 
counted and centrifuged for 5 minutes at 1,500 rpm and 4 °C. Depending on the 
experiment, cells were resuspended in: PBS with 2% FBS; Complete RPMI 1640 
medium, made complete with 10% FBS and 500 units of penicillin and 500 µg of 
streptomycin; or Transfection RPMI 1640, composed of 10% FBS and 50mM 2-
mercaptoethanol (2-ME; Gibco) 
 
2.3.2 Lymphocyte isolation from spleen 
Spleens were obtained from WT and tumor-bearing mice. Each spleen was pressed 
through a 40 µm Falcon Cell Strainer into RPMI 1640 medium. The cells were loaded 
onto 5 mL of Ficoll-Paque (Fisher Scientific, Ottawa, ON) and centrifuged for 25 
minutes at 2300 rpm and 20 °C with low acceleration and no deceleration. The middle 
lymphocyte layer was transferred and resuspended into a fresh tube of RPMI 1640. Cells 
were counted and centrifuged for 5 minutes at 1,500 rpm and 4 °C. Finally, the cells were 
resuspended in PBS with 2% FBS. 
 
2.3.3 Lymphocyte isolation from tumor tissue 
Tumor tissue was obtained from B16F10 tumor-bearing C57BL/6 mice. The tumor tissue 
was digested in Collagenase IV (Life Technologies) for 30 minutes at 37 °C, while being 
vortexed every 10 minutes, and then was pressed through a 40 µm Falcon Cell Strainer 
into RPMI 1640 medium. Cells were stained with antibodies from the Pan T Cell 
Isolation Kit II (Miltenyi Biotec, MA, USA) as per the manufacturer’s instruction and run 
through a magnetic MACS column to isolate unstained T cells. Cells were counted and 
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centrifuged for 5 minutes at 1,500 rpm and 4 °C before resuspension in PBS with 2% 
FBS. 
 
2.4 Flow cytometry and cell sorting 
Flow cytometry was performed using a BD LSR II (BD Biosciences, Mississauga, ON) 
and cell sorting with a BD FACS Aria III (BD Biosciences, Mississauga, ON). One 
million cells were suspended in 100 µL of PBS with 2% FBS and stained with 0.2 µg of 
CD3-FITC, CD4-FITC, CD8-FITC, PD1-PerCP-eFluor 710, TIM3-PE, BTLA-APC, Rat 
IgG2b Isotype Control-PerCP-eFluor 710, Mouse IgG2a K Isotype Control-PE, Mouse 
IgG1 K Isotype Control-APC (eBioscience, San Diego, CA) or 0.1 µg of Fixable 
Viability Dye eFluor 506 (eBioscience) for 30 minutes at 4 °C. Cells were washed with 2 
mL of PBS with 2% FBS, centrifuged for 5 minutes at 1,500 rpm and 4 °C, and 
resuspended in the same medium before flow cytometric analysis and sorting. 
 
2.5 miRNA extraction and cDNA synthesis 
The miRNeasy Mini Kit (Qiagen, Toronto, ON) was used to isolate total RNA including 
miRNAs. 700 µL of QIAzol Lysis Reagent was added to lymphocyte cell pellets and 
homogenized by vortexing. After 5 minutes of incubation at room temperature, 140 µL of 
chloroform was added and the tube was shaken vigorously for 15 seconds and incubated 
at room temperature for 3 minutes. The mixture was centrifuged at 12,000 x g for 15 
minutes at 4 °C. The upper aqueous phase was transferred to a new tube and mixed with 
1.5 times the volume of 100% ethanol. 700 µL of the mixture was filtered through an 
RNeasy Mini Column at 12,000 x g for 15 second, discarding the flow through. 700 µL 
of Buffer RWT, and two washes of 500 µL of Buffer RPE were filtered through the 
column with centrifugation. 50 µL of RNase free water was used to elute the total RNA 
with centrifugation at 12,000 x g for 2 minutes. RNA concentration was measured using a 
NanoDrop ND-1000 (Thermo Scientific, Ottawa, ON).  
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200 ng of total RNA was used with the miScript II Reverse Transcriptase Kit 
(Qiagen). In 200 µL tubes, RNA and water were combined to 12 µL and 4 µL of 5x 
miScript HiSpec Buffer, 2 µL of 10x Nucleic Mix and 2 µL of Reverse Transcriptase 
Mix was added for a total volume of 20 µL. Tubes were incubated at 37 °C for 60 
minutes and then the reverse transcriptase was inactivated with incubation at 95 °C for 5 
min. cDNA was placed on ice prior to use in reverse transcription quantitative 
polymerase chain reaction (RT-qPCR). 
 
2.6 mRNA extraction and cDNA synthesis 
Total RNA was extracted from cells using 0.5 mL of Trizol reagent (Invitrogen, 
Burlington, ON). 250 µL of chloroform was added and mixed vigorously, and the 
mixture was incubated for 5 min at room temperature before centrifugation at 12,000 x g 
for 15 minutes at 4 °C. The aqueous layer was removed, mixed with 0.5 mL isopropanol 
and mixed vigorously before incubation for 10 minutes at room temperature. A pellet was 
formed after centrifugation at 12,000 x g for 10 minutes at 4 °C and washed with 0.5 mL 
of 75% ethanol. After washing, pellets were air dried and resuspended in RNase free 
water (Life Technologies) and incubated for 10 minutes at 60 °C. RNA concentration was 
measured using a NanoDrop ND-1000. 
2 µg of mRNA was used for reverse transcription. First, 15.5 µL RNA in RNase 
free water and 1 µL oligo-(dT) (0.5µg/µL) were mixed and incubated at 70 °C for 10 
minutes. 2 µL of 10x 1st strand buffer, 1 µL of 10mM (deoxyribonucleotide 
triphosphates) dNTPs and 0.5 µL of reverse transcriptase (100 units) (Invitrogen) were 
added to the reaction mixture. The tube was incubated at 42 °C for 50 minutes and 
reverse transcriptase was inactivated at 70 °C for 15 minutes. Finally, cDNA was placed 
on ice before use in RT-qPCR. 
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2.7 miRNA array analysis 
The Affymetrix GeneChip 3.0 miRNA Array (Affymetrix, Santa Clara, CA) was used 
with the FlashTag Biotin HSR RNA Labeling Kit (Affymetrix). To begin, a poly(A) tail 
was added to each RNA strand. 500 ng of total RNA containing miRNAs was adjusted to 
8 µL in nuclease-free water. Next, 2 µL of RNA Spike Control Oligos was added and the 
tube was placed on ice. A master mix was made that consisted of the following reaction 
mixture per RNA sample: 1.5 µL 10X Reaction Buffer, 1.5 µL 25 mM MnCl2, 1.0 µL 
Diluted ATP Mix and 1.0 µL Poly A Polymerase Enzyme. The 5 µL of master mix was 
added to the 10 µL RNA/Spike Control tube for a final volume of 15 µL. The mixture 
was spun down in a microfuge and incubated at 37 °C for 15 minutes.  
After addition of a poly(A) tail, the RNA was tagged with Biotin-labeled RNA. 4 
µL of 5X FlashTag Biotin HSR Ligation Mix and 2 µL of T4 DNA Ligase was added to 
each 15 µL poly(A) RNA sample. The tube was mixed by pipetting, microcentrifuged 
and incubated at room temperature for 30 minutes. After, the reaction was stopped by 
adding 2.5 µL HSR Stop Solution and the solution was mixed by pipetting and 
microcentrifuged. 2 µL was removed to confirm quality using the Enzyme Linked 
Oligosorbent Assay (Affymetrix) 
The next step involved hybridizing the biotin-labelled RNA to the miRNA array. 
The hybridization cocktail was made by mixing the following reagents: 66 µL 2X 
Hybridization Mix, 19.2 µL 27.5% Formamide, 12.8 µL DMSO, 6.6 µL 20X 
Hybridization Controls, 2.2 µL Control Oligo B2 (3 nM) and 3.7 µL nuclease-free water 
for a total volume of 110.5 µL. The 110.5 µL hybridization cocktail was added into the 
remaining 21.5 µL of biotin-labeled RNA. The final mixture was incubated at 99 °C for 5 
minutes, followed by another 5 minute incubation at 45 °C. The 130 µL mixture was 
injected into the Affymetrix GeneChip 3.0 miRNA Array and the arrays were loaded into 
a preheated Affymetrix Hybridization Oven 645 (Affymetrix) at 48 °C and 60 rpm for 16 
hours. A list of probes sequences on the miRNA array for the various miRNAs studied in 
this project are listed in Table 2.1. 
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Table 2.1 Affymetrix GeneChip 3.0 miRNA Array miRNA probe sequences 
Mature miRNA Probe Sequence (5’  3’) 
miR-103 TCATAGCCCTGTACAATGCTGCT 
miR-107 TGATAGCCCTGTACAATGCTGCT 
miR-146a AACCCATGGAATTCAGTTCTCA 
miR-150 CACTGGTACAAGGGTTGGGAGA 
miR-151-5p ACTAGACTGTGAGCTCCTCGA 
miR-155 ACCCCTATCACAATTAGCATTAA 
miR-181a ACTCACCGACAGCGTTGAATGTT 
miR-21 TCAACATCAGTCTGATAAGCTA 
miR-23a GGAAATCCCTGGCAATGTGAT 
miR-27a GCGGAACTTAGCCACTGTGAA 
miR-28 CTCAATAGACTGTGAGCTCCTT 
miR-30b AGCTGAGTGTAGGATGTTTACA 
miR-378b TCTTCTGACTCCAAGTCCAG 
miR-466c-5p ATATGTACATGCACACACACATCA 
miR-467a CGCATATACATGCAGGCACTTA 
miR-5121 GGAGATGTCTCATCACAAGCT 
miR-669a-3p ATACGTGTGTGTGTATGTTATGT 
miR-669a-5p AGACATGAACATGCACACACAACT 
miR-let-7e AACTATACAACCTCCTACCTCA 
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 After hybridization, the hybridization cocktail was extracted from each array and 
the array was filled with Array Holding Buffer. After equilibrating to room temperate, the 
arrays were stained using the Fluidics Station 450 (Affymetrix) with the appropriate 
fluidics and fluidics script for the array format.  
 Lastly, after staining and washing the array was scanned using the GeneChip 
Scanner 3000 and Affymetrix GeneChip Command Console software (Affymetrix). The 
analysis of miRNA data was performed using the Partek Genomics Suite (Partek, St. 
Louis, MO). 
 
2.8 Real-time quantitative PCR 
Primers for RT-qPCR detection of significantly altered miRNAs discovered from the 
miRNA array are unique in the sense that they extend the cDNA of the miRNA for 
detection by quantitative PCR. The primer sequences are not available, but a list of their 
targets is displayed in Table 2.2. Real-time PCR reactions were performed in a Stratagene 
Mx3000P QPCR System (Agilent Technologies, Lexington, MA) using the miScript 
SYBR green PCR Kit (Qiagen) and miScript Primer Assay (Qiagen). The reaction 
mixture contained: 10 µL 2x QuantiTect SYBR Green PCR Master Mix, 2 µL 10x 
miScript Universal Primer, 2 µL 10x miScript Primer Assay and 6 µL of cDNA mix in 
RNase-free water for a total volume of 20 µL. The PCR reaction conditions for miRNA 
analysis was 95 °C for 15 min, and 94 °C for 15 seconds, 55 °C for 30 seconds and 70 °C 
for 30 seconds (40 cycles). Each miRNA primer was referenced to Homo sapiens small 
nucleolar RNA, C/D box 61 (SNORD61) and normalized to PD1- cells using the 2-ΔΔCt as 
described by Livak and Schmittgen [104]. 
  qPCR detection of GAPDH silencing in T cells using siRNA was analyzed in a 
Stratagene Mx3000P QPCR System (Agilent Technologies, Lexington, MA) with SYBR 
Green PCR Master Mix (Life Technologies). The reaction mixture was composed of 10 
µL of 2x SYBR Green PCR Master Mix, 100 ng of cDNA, 100 nM primers for GAPDH 
and β-Actin (Table 2.3), and RNase-free water brought up to 20 µL. The PCR reaction 
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Table 2.2 Target sequences of miRNA primers for real time qPCR analysis 
Mature miRNA miRNA Target Sequence (5’  3’) 
miR-103 AGCAGCAUUGUACAGGGCUAUGA 
miR-107 AGCAGCAUUGUACAGGGCUAUCA 
miR-146a UGAGAACUGAAUUCCAUGGGUU 
miR-150 UCUCCCAACCCUUGUACCAGUG 
miR-151-5p UCGAGGAGCUCACAGUCUAGU 
miR-155 UUAAUGCUAAUUGUGAUAGGGGU 
miR-181a AACAUUCAACGCUGUCGGUGAGU 
miR-21 UAGCUUAUCAGACUGAUGUUGA 
miR-23a AUCACAUUGCCAGGGAUUUCC 
miR-27a UUCACAGUGGCUAAGUUCCGC 
miR-28 AAGGAGCUCACAGUCUAUUGAG 
miR-30b UGUAAACAUCCUACACUCAGCU 
miR-378b CUGGACUUGGAGUCAGAAGA 
miR-466c-5p UGAUGUGUGUGUGCAUGUACAUAU 
miR-467a UAAGUGCCUGCAUGUAUAUGCG 
miR-5121 AGCUUGUGAUGAGACAUCUCC 
miR-669a-3p ACAUAACAUACACACACACGUAU 
miR-669a-5p AGUUGUGUGUGCAUGUUCAUGUCU 
miR-let-7e UGAGGUAGGAGGUUGUAUAGUU 
SNORD61 GCTATGATGAATTTGATTGCATTGA 
TCGTCTGACATGATAATGTATTTTT 
GTCCTCTAAGAAGTTCTGAGCTT 
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Table 2.3 Primers used in RT-qPCR detection of mRNA levels 
Mature miRNA miRNA Target Sequence (5’  3’) 
GAPDH Forward TGATGACATCAAGAAGGTGGTGAA 
GAPDH Reverse TCCTTGGAGGCCATGTAGGCCAT 
Β-Actin Forward AGGGAAATCGTGCGTGACATCAAA 
Β-Actin Reverse ACTCATCGTACTCCTGCTTGCTGA 
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conditions were: 95°C for 10 minutes followed by 40 cycles at 95°Cfor 30 seconds, 58°C 
for 1 minute and 72°C for 30 seconds. Relative GAPDH gene expression was calculated 
with 2-ΔΔCt using β-Actin as a reference gene. 
 
2.9 In silico analysis 
In silico analysis was performed by accessing multiple miRNA databases: miRanda, 
TargetScan Mouse 6.2 and PicTar. In each database, miRNAs were searched that had 
complementarity to the 3’ UTRs of PD1, TIM3 and BTLA. Only miRNAs that were 
7mer or 8mer were considered. There are 2 types of 7mer and 1 type of 8mer binding: 
7mer-m8 and 8mer miRNAs bind in positions 2-8 of the seed region and 7mer-1A 
miRNAs bind in positions 2-7 in the seed region with position 8 bound to an A on the 
mRNA. 
 
2.10 pmirGLO dual luciferase plasmid 
2.10.1 PD1 3’ UTR amplification 
The 3’ UTR of PD1 was amplified using PCR. cDNA from WT C57BL/6 lymphocytes 
were used in a reaction mixture that contained: 19.8 µL nuclease free water, 2.5 µL 10x 
PCR buffer, 0.5 µL of 10 µM forward and reverse primer (Table 2.4), 0.5 µL 10 mM 
dNTPs, 0.2 µL of 5U/ µL Taq polymerase (Invitrogen) and 1 µL cDNA. Sample was 
thermocycled at 94 °C for 3 minutes, and run through 40 cycles at 94 °C for 30 seconds, 
58 °C for 30 seconds and 72 °C for 30 seconds before a final incubation at 72 °C for 10 
minutes. 
The amplified cDNA was run on a 1.5% agarose gel and the QIAquick Gel 
Extraction Kit (Qiagen) was used to isolate the DNA from reaction mixture components. 
The DNA fragment was excised from the agarose gel and 3 volumes of buffer QG was 
added to 1 volume of gel (100 mg ~ 100 µL). After a 10 minute incubation at 50 °C, 1 gel 
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Table 2.4 PD1 3’ UTR primer sequences 
Primer Name Primer Sequence (5’  3’) 
PD1 3’ UTR Forward ATATACTCGAGCCAGATTCTTCAGCCATTAGCATG 
CT 
PD1 3’ UTR Reverse GCGTGTCTAGATTTAAAGCTTTTGGTACCATTTAA 
TTATAACGGGCT 
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volume of isopropanol was added to the sample and mixed by inverting the tube. The 
sample was applied to a QIAquick column and centrifuged for 1 minute at 12,000 x g.  
The flow through was discarded and two washes were done using 500 µL of buffer QG1 
and then 750 µL of buffer PE followed by centrifugation for 1 minute at 12,000 x g for 
each wash. The QIAquick column was placed in a new Eppendorf tube and 50 µL of 
buffer EB was added onto the membrane to elute the DNA. 
 
2.10.2 Restriction enzyme digestion and ligation 
500 ng of amplified PD1 3’ UTR and pmirGLO Dual Luciferase Plasmid were cut with 
XhoI and XbaI restriction enzymes (New England Biolabs, Ipswich, MA). The plasmid 
and PD1 3’ UTR were cut in separate tubes that contained both restriction enzymes. 12 
units of each restriction enzyme were used in a total volume of 28 µL consisting of 10x 
buffer and nuclease free water. The reaction mixture was incubated at 37 °C for 30 
minutes. 50 ng of cut plasmid and 35 ng of cut insert were ligated overnight at 16 °C. The 
ligation used a 5:1 molar ratio of insert:vector and a T4 DNA ligase (New England 
Biolabs), in a total volume of 20 µL. 
 
2.10.3 Amplification and sequencing 
The PD1 3’ UTR pmirGLO Dual Luciferase Plasmid was amplified in JM109 cells 
(Promega, Madison, WI). First, JM109 cells were thawed on ice for 5 minutes and mixed 
before transferring 50 µL to a chilled sterile polypropylene culture tube. 25 ng of PD1 3’ 
UTR pmirGLO plasmid was added to the competent cells and placed on ice for 10 
minutes. Cells were heat-shocked at 42 °C for 45 seconds, placed on ice for 2 minutes, 
added to 450 µL of lysogeny broth (LB; Life Technologies) containing 100µg/mL 
ampicillin (Bioshop, Richmond, BC) and were shaken at 37 C° for 60 minutes. All 500 
µL was plated on ampicillin containing LB plates overnight, and afterwards clones were 
isolated and shaken overnight at 37°C in 5 mL of LB broth containing ampicillin. 
Plasmid was extracted using the GeneJET Plasmid Miniprep Kit (Fermentas, Burlington, 
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ON). Cells were pelleted in a centrifuge and resuspended in 250 µL of resuspension 
solution. 250 µL of lysis solution was added and mixed by inverting the tube, and then 
350 µL of neutralization solution was added and mixed by inverting the tube. Cells were 
centrifuged for 5 minutes at 12,000 x g. The supernatant was transferred to a GeneJET 
spin column and centrifuged for 1 minute at 12,000 x g. The flow through was discarded 
and two washes of 500 µL wash solution was added and the column centrifuged for 1 
minute at 12,000 x g each time. The plasmid was eluted from the column by adding 50 
µL of elution buffer, waiting 2 minutes and centrifuging the columns at t 12,000 x g for 2 
minutes. The concentration of the plasmid was then measured using a NanoDrop ND-
1000. 
Sequencing was done using the BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, Foster City, CA). Initially, 1.5 µg of PD1 3’ UTR pmirGLO 
plasmid was brought up to a final volume of 20 µL in nuclease-free water after the 
following reaction conditions were added: 8 µL Terminator Ready Reaction Mix and 2 
µL of 2µM PD1 3’ UTR forward primer (Table 2.4). The sample was mixed briefly, and 
spun down before cycle sequencing was performing on a GeneAmp PCR System 9600 
(Applied Biosystems). Tubes were heated to 95 °C for 5 minutes and then cycled 50 
times at 95 °C for 30 seconds, 55 °C for 10 seconds and 60 °C for 4 minutes. Tubes were 
cooled down to 4 °C before purification of extension products using the Performa DTR 
V3 96-Well Short Plate Kit (Edge Biosystems, Gaithersburg, MD). Lastly, sequencing of 
purified extension product was performed in an Applied Biosystems 3730 DNA 
Analyzer.  
 
2.10.4 Plasmid and miRNA mimic transfection  
The list of miRNA mimics (Qiagen) transfected with the PD1 3’ UTR pmirGLO plasmid 
are shown in Table 2.5. 60,000 B16F10 cells per well were plated overnight before 
transfection in 24 well plates using culture medium. On the day of transfection, cells were 
washed with PBS and 300 µL of Opti-MEM was added. In an Eppendorf tube, 0.2 µg of  
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Table 2.5 miRNA mimic sequences / miRNA inhibitor targets 
miRNA mimic miRNA sequence (5’  3’) 
miR-28 AAGGAGCUCACAGUCUAUUGAG 
miR-150 UCUCCCAACCCUUGUACCAGUG 
miR-103 AGCAGCAUUGUACAGGGCUAUGA 
miR-107 AGCAGCAUUGUACAGGGCUAUCA 
mimic control The AllStars Negative Control siRNA sequence is not 
available, but it has no homology to any known 
mammalian gene (Qiagen #SI03650318) 
inhibitor control The miRNA inhibitor control sequence is not available, 
but it is designed to target the AllStars Negative Control 
siRNA and has no homology to any known mammalian 
gene (Qiagen #1027271) 
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plasmid and 1 µg of miRNA mimic were added to 100 µL of Opti-MEM. In a separate 
tube, 100 µL of Opti-MEM was mixed with 2.4 µL of Lipofectamine 2000 Transfection 
Reagent (Life Technologies) in a 1:2 ratio of miRNA + plasmid (µg):Lipofectamine 2000 
(µL). After 5 minutes of room temperature incubation, both tubes were mixed and 
allowed to incubate for 20 minutes at room temperature. Then the 200 µL mixture of 
Opti-MEM, miRNA mimic and dual luciferase plasmid was added into each well of 
plated B16F10 cells. After 4 hours incubating at 37 °C and 5% CO2, the wells were 
topped off with culture medium with 20% FBS and placed back at 37 °C and 5% CO2 for 
24 hours before analysis in a Lumat LB 9507 luminometer (Berthold Technologies, Oak 
Ridge, TN). 
 
2.10.5 Dual Luciferase Assay 
The Dual-Luciferase Reporter Assay System (Promega) was used to detect firefly and 
renilla luciferase from the PD1 3’ UTR pmirGLO plasmid. 24 hours after transfection 
with plasmid and miRNA mimic, B16F10 cells were washed with PBS in preparation for 
lysis. Cells were no more than 95% confluent at the time of lysis. 100 µL of passive lysis 
buffer was added to each well and the plate was rocked gently for 15 minutes. The lysate 
was transferred to an Eppendorf tube for detection in a Lumat LB 9507 luminometer 
(Berthold Technologies). 100 µL of Luciferase Assay Reagent II was predispensed in 
polypropylene tubes and 20 µL of cell lysate was added and mixed by pipetting. After a 
10 second measurement for firefly luciferase activity, 100 µL of Stop & Glo reagent was 
added and the tube was vortexed. The sample was placed back in the luminometer and 
renilla luciferase activity was measured for 10 seconds. Each sample was read twice, and 
luciferase activity (firefly luciferase/renilla luciferase) was normalized to the miRNA 
mimic control and PD1 3’ UTR pmirGLO transfection. 
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2.11 Lymphocyte treatment with anti-CD3e and IFNγ 
Lymphocytes isolated from lymph nodes of C57BL/6 mice were treated with anti-CD3e 
(BD Biosciences) or IFNγ (Peprotech, QC) by plating 2 million cells in 24 well plates. 
For treatment with anti-CD3e, the plates were coated with various concentrations (from 0 
– 25 µg/mL) of anti-CD3e in 200 µL of PBS overnight at 4 °C. Plates were washed with 
PBS before lymphocytes were plated in Complete RPMI 1640. Treatment with IFNγ 
involved adding various concentrations (0 – 20 ng/mL) to the well at the time of plating. 
With both treatments, lymphocytes were incubated at 37 °C and 5% CO2 for 24 hours 
before cells were collected for flow cytometry. 
 
2.12 T cell transfection with siRNA, miRNA mimics and 
inhibitors 
Lymphocytes from the lymph nodes of WT C57BL/6 mice were plated 2 million per well 
in a 24 well plate using 400 µL of RPMI 1640 with 10% FBS and 50 mM 2-ME 
(Transfection RPMI 1640 medium). 1 µg of miRNA mimic, miRNA inhibitor (Qiagen) 
(Table 2.5) or siRNA (Ambion, Austin, TX) (Table 2.6) was added to 50 µL of Opti-
MEM and various ratios of transfecting reagent was added to a separate tube with 50 µL 
of Opti-MEM. A 2:1, 1:1, 1:2, 1:4 and 1:6 ratio of siRNA (µg):transfection reagent (µl) 
was used for the initial experiments on T cell transfections and a 2:1 ratio was used for 
the rest. After 5 minutes of room temperature incubation, the RNA and transfection 
reagent tubes were combined and incubated for 20 minutes at room temperature. The 100 
µL mixture was then added to each well. After 4 hours of incubation at 37 °C and 5% 
CO2, 500 µL of Transfection RPMI 1640 was added to each well and the plates were 
incubated for up to 48 hours at 37 °C and 5% CO2 before cells were collected for various 
experiments. 
 
 
29 
 
 
 
Table 2.6 Small interfering RNA sequences 
Gene siRNA sequence (5’  3’) 
GAPDH The Silencer Cy3-labelled GAPDH siRNA sequence is 
not available (Ambion #AM4649) 
control siRNA The negative control siRNA sequence is not available, 
but it has no significant homology to any known gene 
sequences from mice, rats or humans (Ambion 
#AM4611) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
 
 
2.13 Analysis of proliferation and apoptosis using flow 
cytometry 
For functional analysis of CD4+ T cells after miRNA mimic transfection, CD4 MACS 
beads (Miltenyi Biotec) were used to purify CD4+ T cells before flow cytometric 
analysis. The cells were stained as per manufacturer’s instructions and run through a 
magnetic column to positively isolate the CD4+ T cells. 
To visualize cell proliferation, lymphocytes were transfected as described in 2.12 
and stained with carboxyfluorescein succinimidyl ester (CFSE; eBioscience) prior to 
plating on anti-CD3e coated plates. After transfection, cells were suspended 50 x 106 
cells/mL in PBS and CFSE was added to a final concentration of 5 µM. Cells were mixed 
rapidly to evenly disburse the CFSE and incubated at room temperature for 5 minutes. 
Cells were wash with 10 volumes of PBS containing 5% FBS and centrifuged at 1500 
rpm and 20°C for 5 minutes. After 3 washes, the cells were resuspended in Complete 
RPMI 1640 medium and plated on anti-CD3e coated plates for 4 days before CD4 MACS 
bead isolation, PD1 PerCP eFluor 710 staining and analysis by flow cytometry. As cells 
proliferate, the CFSE staining gets split to the daughter cells creating a weaker CFSE 
signal. Therefore, CFSElow signal peaks were gated to quantify the percentage of 
proliferating cells. 
 To measure apoptosis, cells were transfected as described in 2.12, and stained 
with PD1-PerCP-eFluor 710, and Viability Dye eFluor 506 as described in 2.4 after CD4 
MACS beads isolation. After PD1 and viability staining, cells were suspended in 100 µL 
of Annexin V Binding Buffer (BD Biosciences) and 5 µL of Annexin V-FITC (BD 
Biosciences) was added. After a 15 minute incubation at room temperature, 200 µL of 
Annexin V Binding Buffer were added and cells were analyzed by flow cytometry. Cells 
that double stain for eFluor 506 and Annexin V are in late apoptosis, while cells that only 
stain for Annexin V are in early apoptosis. Viable cells stain double negative. 
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2.14 Statistical analysis 
Either a one-way analysis of variance (ANOVA) or a two-tailed unpaired Student’s T test 
was used to determine significance for all experiments. Signification was determined if p 
< 0.05. Further details can be found in each figure legend. 
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Chapter 3  
3 Results 
3.1 PD1 displays increased expression in T cells isolated 
from lymphoid and tumor tissue in a B16F10 mouse 
melanoma model 
To develop a B16F10 murine melanoma model, C57BL/6 mice were injected with 
400,000 B16F10 cells in two spots on their back and tumors were allowed to grow for 16 
days before isolating lymphocytes from the lymph nodes, spleen and tumors. Next, flow 
cytometry was performed to determine the PD1 expression profile in T cell-containing 
tissues between WT and B16F10 injected mice. PD1 expression was significantly 
increased in B16F10 tumor-bearing mice compared to WT mice (Figure 3.1A). On CD4+ 
T cells, PD1 expression significantly increased in the spleens from B16F10 tumor-
bearing mice compared to WT lymph node, WT spleen and B16F10 lymph node (Figure 
3.1B). CD8+ T cells demonstrated a significant increase in B16F10 spleens over WT 
lymph nodes (Figure 3.1B). In the tumor tissue, CD4+ T cells displayed 48.1% PD1 
expression while CD8+ T cells displayed 27.45% PD1 expression (Figure 3.1B). Since 
only approximately 50,000 T cells could be isolated from each tumor, and CD8+ T cells 
express PD1 to a lesser extent, it was decided to sort CD4+ T cells from the lymph nodes 
and spleen for microRNA array analysis. 
 
3.2 11 miRNAs have altered expression in PD1+CD4+ T 
cells 
To analyze the global miRNA expression profile between PD1+ and PD1- T cells, 
PD1+CD4+ and PD1-CD4+ T cells were sorted from lymph nodes and spleen using a 
FACS Aria III and total RNA including miRNA was extracted. 800 ng of RNA was used 
for the Affymetrix GeneChip 3.0 miRNA array. No significant differences were found 
between the miRNA expression profiles of either tissue, so data from the both tissues 
were pooled. A heatmap was generated looking at miRNAs with a fold change of +/- 2,  
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Figure 3.1 CD4+ and CD8+ T cells from lymph nodes, spleens and tumors of B16F10 
tumor-bearing mice express significantly more PD1 than T cells from WT mice. 
CD4+ and CD8+ T cells were isolated from the lymph nodes and spleen of WT mice and 
lymph node, spleen and tumors of B16F10 injected mice. (A) PD1 expression on viable T 
cells was analyzed by flow cytometry. (B) A one-way ANOVA followed by a Tukey’s 
post-hoc test was used to compare PD1 expression levels between tissues. Signification 
was determined if p < 0.05 (* = p < 0.05, ** = p < 0.01 and *** = p < 0.001). The data 
shown are representative of at least two independent experiments. 
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which found 11 significantly downregulated and 8 significantly upregulated miRNAs in 
PD1+CD4+ T cells (Figure 3.2). In order to confirm the results of miRNA array, 200 ng of 
RNA was used for real time RT-qPCR analysis on the 19 miRNAs. Figure 3.3 displays 
discrepancies between the miRNA array and qPCR data, showing that only 3 down 
regulated miRNAs (miR-150, miR-28 and miR-151-5p) and 8 upregulated miRNAs 
(miR-let-7e, miR-103, miR-107, miR-27a, miR-23a, miR-21, miR-155 and miR-146a) 
showed similar trends in altered miRNA expression levels. miR-28, miR-150 and miR-
151-5p expression in PD1+CD4+ T cells decreased by 30%, 45% and 25%, respectively 
(Figure 3.4A) and miR-let-7e, miR-103 and miR-107 increased by 189%, 328% and 
318%, respectively (Figure 3.4B). 5 miRNAs; miR-27a, miR-23a, miR-21, miR-155 and 
miR-146a displayed even greater increases in expression in PD1+CD4+ T cells by 754%, 
932%, 993%, 1239% and 2096%, respectively (Figure 3.4C).  
 
3.3 In silico analysis of miRNAs that may bind to the 3’ UTR 
of PD1, TIM3 and BTLA 
To discover miRNAs that may bind to the 3’ UTR of PD1, TIM3 and BTLA an in silico 
database search was conducted using miRanda, TargetScan and PicTar. Of note, miR-28 
and miR-150 have significant complementarity to all 3 inhibitory immunoreceptors, and 
miR-103 and miR-107 were complementary to PD1 and BTLA (Table 3.1 and Figure 
3.5). Therefore, in accordance with the miRNA array data, these 4 miRNAs were chosen 
as candidates for further study. 
 
3.4 miR-28 and miR-107 silence PD1 through its 3’ UTR 
To determine whether any of the 4 candidates could silence PD1 through its 3’ UTR, a 
dual luciferase assay was conducted. The 3’ UTR of PD1 was amplified from WT 
C57BL/6 lymph nodes and ligated into the pmirGLO Dual Luciferase miRNA Target 
Expression Vector (Promega, USA) directly downstream of firefly luciferase. B16F10  
36 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 19 miRNAs have significantly altered expression between CD4+PD1- and 
CD4+PD1+ T cells isolated from tumor-bearing mice. Using the Affymetrix GeneChip 
3.0 miRNA Array a total of 1,966 mouse miRNAs were analyzed in PD1+ and PD1- 
CD4+ T cells. The heat maps represent 19 miRNAs with a fold change greater than +/- 2 
between CD4+PD1- and CD4+PD1+ samples. The left heat map shows fold changes 
between CD4+PD1- and CD4+PD1+ T cells from three individual experiments, and the 
right heat map shows the average fold-change from all samples. 
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            miRNA array between CD4+PD1+ and CD4+PD1- T cells 
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Figure 3.3 Fold changes in miRNA expression between PD1+CD4+ and PD1-CD4+ T 
cells determined by the miRNA array and qPCR data. In order to discover 
discrepancies between the miRNA array and qPCR data, fold-changes were compared 
and only the miRNAs with equal trends were considered for further study. The data 
shown are representative of three independent experiments. 
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Figure 3.4 RT-qPCR confirms 11 significantly up- and downregulated miRNAs 
discovered in the microRNA array. (A) Significantly downregulated miRNAs in 
PD1+CD4+ T cells that show an equal trend between the miRNA array and qPCR data. 
(B-C) Significantly upregulated miRNAs in PD1+CD4+ T cells that show an equal trend 
between the miRNA array and qPCR data. Significance (p < 0.05) between PD1- and 
PD1+CD4+ T cells was determined using an unpaired student’s T test (* = p < 0.05, ** = 
p < 0.01 and *** = p < 0.001). Data are representative of three independent experiments. 
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Table 3.1 miRNA candidates that may silence PD1, TIM3 and BTLA in various 
combinations. In silico analysis using miRanda, TargetScan and PicTar to discover 
miRNA candidates that may silence PD1, TIM3 and BTLA in various combinations. The 
bolded miRNAs represent candidates that were chosen for further study. 
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miRNA candidates that may silence PD1, TIM3 and BTLA in various combinations 
 
PD1 & TIM3 PD1 & BTLA TIM3 & BTLA PD1, TIM3 & BTLA 
mmu-miR-28 mmu-miR-28 mmu-miR-28 mmu-miR-28 
mmu-miR-150 mmu-miR-150 mmu-miR-150 mmu-miR-150 
mmu-miR-708 mmu-miR-708 mmu-miR-708 mmu-miR-708 
mmu-miR-370 mmu-miR-103 mmu-miR-544  
 mmu-miR-107   
 mmu-miR-154   
 mmu-miR-320   
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Figure 3.5 Candidate miRNA alignment on the 3’ UTRs of PD1, BTLA and TIM3 
mRNA. The theoretical bindings sites for miR-28, miR-150 and miR-103/107 on the (A) 
PD1, (B) BTLA and (C) TIM3 3’ UTR. Each miRNA-mRNA combination displays the 
miRNA, murine 3’ UTR and human 3’ UTR sequences from top to bottom. Since the 
sequences for miR-103 and miR-107 differ by only one nucleotide, the * represents a G 
and C, respectively. The vertical black lines and red nucleotides represent base-pairing 
between the miRNA and the murine (mmu) 3’ UTR, while the red nucleotides in the 
human (hsa) 3’ UTR are complementary to the miRNA. The number in the bracket 
denotes the distance in nucleotides from the start of the 3’ UTR to the start of the miRNA 
seed region. 
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cells were used to transfect the dual luciferase plasmid with miRNA mimics or control 
miRNA, and 24 hours later cells were collected and analyzed through a luminometer for 
firefly and renilla luciferase activity. Data showed (Figure 3.6) that miR-28 and miR-107 
reduced luciferase activity to 50 and 40%, respectively, while miR-150 and miR-103 had 
no regulatory effect on the luciferase activity indicating that miR-28 and miR-107 bind to 
the 3’ UTR of the PD1 gene. 
 
3.5 Anti-CD3e, but not IFNγ, upregulates PD1 and BTLA 
expression in vitro 
In order to determine if the miRNA expression is altered as a response to PD1 
upregulation, rather than a causation, an in vitro system needed to be discovered that 
could upregulate inhibitory immunoreceptor expression. Two methods were attempted, 
which involved culturing lymphocytes on anti-CD3e coated plates or exposing the cells 
to IFNγ. CD3e stimulation alone, without a CD28 co-activation signal causes the T cell to 
undergo anergy, a very similar process to T cell exhaustion. As well, previous research 
has shown that IFNγ upregulated PD-L1 expression on human uveal melanoma cells, 
thus we were curious to discover if IFNγ affects PD1 expression on T cells [105]. 
Initially, 2 million lymphocytes were plated in 24 well plates that were coated with 0, 1, 
10 or 25 µg/mL of anti-CD3e overnight or exposed to 0, 1, 5, 10 or 20 ng/mL of IFNγ in 
the cell culture medium. Cells were cultured for 24 hours and analyzed by flow 
cytometry. Anti-CD3e treatment significantly increased PD1 and BTLA expression on 
CD4+ and CD8+ T cells in a dose depending manner (Figure 3.7). On the other hand, 
IFNγ had no observable effect on inhibitory immunoreceptor expression (Figure 3.8). 
Therefore, 10 µg/mL of anti-CD3e was used for subsequent experiments. 
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Figure 3.6 miR-28 and miR-107 bind to and silence the PD1 3’ UTR. Dual Luciferase 
Assay of pmirGLO Plasmid with PD1 3’ UTR insert and miRNA mimics. B16F10 cells 
were transfected with the PD1 3’ UTR dual luciferase plasmid and either miRNA mimic 
or mimic control. Luciferase Activity was measured with a luminometer and normalized 
to mimic control. A one-way ANOVA followed by a Dunnett’s multiple comparison test 
between miRNA mimic and control was used for statistical analysis, significance was 
determined if p < 0.05. The data shown represent three independent experiments. 
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Figure 3.7 Anti-CD3e treatment increases PD1 and BTLA expression in a dose-
dependent manner. Percent of PD1, TIM3 and BTLA expression on viable CD4+ or 
CD8+ T cells after treatment with various concentrations of anti-CD3e. Lymphocytes 
were isolated from lymph nodes of WT C57BL/6 mice and 2 million cells/well were 
plated in a 24-well plate, which was coated with various concentrations of anti-CD3e 
antibody the night before. 24 hours after plating, cells were stained with Viability Dye 
eFluor 506, CD4-FITC, CD8-FITC, PD1-PerCP-eFluor 710, TIM3-PE and BTLA-APC, 
and analyzed by flow cytometry. (A) PD1 expression (B) TIM3 expression (C) BTLA 
expression. For both T cell subtypes, a one-way ANOVA followed by a Dunnett’s 
multiple comparison test was used to compare immunoreceptor expression alterations 
between treatment and non-treatment with anti-CD3e. Signification was determined if p < 
0.05 (* = p < 0.05, ** = p < 0.01 and *** = p < 0.001). The data shown are representative 
of three independent experiments. 
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Figure 3.8 IFNγ treatment has no effect on PD1, TIM3 or BTLA expression. Percent 
of PD1, TIM3 and BTLA expression on viable CD4+ or CD8+ T cells after exposure to 
various concentrations of IFNγ. Lymphocytes were isolated from lymph nodes of WT 
C57BL/6 mice and 2 million cells/well were plated in a 24-well plate. 0, 1, 5, 10 or 20 
ng/mL of IFNγ was added to the wells and cells were incubated at 37 °C for 24 hours. 
Flow cytometric analysis was performed after cells were stained with Viability Dye 
eFluor 506, CD4-FITC, CD8-FITC, PD1-PerCP-eFluor 710, TIM3-PE and BTLA-APC. 
(A) PD1 expression (B) TIM3 expression (C) BTLA expression. For both T cell 
subtypes, a one-way ANOVA followed by a Dunnett’s multiple comparison test was used 
to compare immunoreceptor expression alterations between treatment and non-treatment 
with IFNγ. The data shown are representative of three independent experiments. 
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3.6 miR-28, miR-150, miR-103 and miR-107 show 
decreased expression after anti-CD3e treatment 
To determine if the miRNA levels discovered in CD4+PD1+ T cells from B16F10 tumor-
bearing mice were a result of increased PD1 expression, 2 million lymphocytes were 
plated per well in a 24 well plate coated with anti-CD3e (10 µg/mL). 24 hours later 
lymphocytes were collected and CD4+ T cells purified using MACS beads. RNA was 
isolated and the expression of the 4 candidate miRNAs was measured with RT-qPCR. 
Expression was normalized to non- stimulated CD4+ T cells, resulting in a significant 
down regulation of the 4 candidate miRNAs. miR-28, miR-150, miR-103 and miR-107 
were downregulated to 41.3%, 22.2%, 51.9% and 42.8%, respectively (Figure 3.9). 
 
3.7 miR-28 and miR-107 inhibitors increase PD1 
expression in CD4+ T cells in vitro 
The next step was to reevaluate how these miRNAs may effect inhibitory 
immunoreceptor expression in a more physiologically relevant state, by transfecting T 
cells. Although my lab focuses on the immune system in cancer, no one has previously 
attempted to transfect T cells, so the first step was to optimize the protocol to achieve a 
high transfection efficiency and viability, and then to demonstrate the ability to 
knockdown a gene. 1 µg of GAPDH-Cy3 siRNA was transfected into 2 million 
lymphocytes with varying amounts of Lipofectamine 2000 or Lipofectamine RNAiMAX. 
Figure 3.10 shows a representative histogram for each group, demonstrating that 
Lipofectamine 2000 had a superior T cell transfection efficiency after 24 hours compared 
to RNAiMax. Next, the optimal transfection ratio of siRNA (µg):Lipofectamine 2000 
(µL) was determined to be 2:1, which achieved a transfection efficiency of 62.7% and 
total viability of 29.8% 48 hours after transfection (Figure 3.11). To prove that the 
optimized transfection efficiency resulted in gene knockdown, lymphocytes were 
transfected with GAPDH siRNA, control siRNA or left alone. 48 hours later, T cells were 
isolated using Pan T Cell Isolation Kit II MACS beads and RNA was purified for use in  
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Figure 3.9 miR-28, miR-150, miR-103 and miR-107 decrease expression after PD1 
upregulation mediated by anti-CD3e binding. Altered miRNA expression in CD4+ T 
cells treated with anti-CD3e. Two million lymphocytes were collected from WT 
C57BL/6 lymph nodes and plated in a 24 well plate coated with 10 µg/mL of anti-CD3e. 
24 hours later CD4+ T cells were isolate using MACS beads and total RNA, including 
miRNAs, were isolated and used for real time RT-qPCR to determine the changes in 
miR-28, miR-150, miR-103 and miR-107 expression after PD1 upregulation mediated by 
anti-CD3e. Significance (p < 0.05) was determined using an unpaired student’s T test. 
Data are representative of three independent experiments. * = p < 0.05, ** = p < 0.01 and 
*** = p < 0.001. 
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Figure 3.10 Lipofectamine 2000 demonstrates greater transfection efficiency in T 
cells comparted to Lipofectamine. 2 million lymphocytes were plated in 24 well plates 
and 1 µg of GAPDH-Cy3 siRNA was transfected for 24 hours using a 1:2, 1:4, 1:6 or 1:8 
ratio of siRNA (µg):transfection reagent (µL) and transfection efficiency was observed 
using flow cytometry. Data are displayed as a histogram showing representative 
efficiency of three independent experiments of GAPDH-Cy3 siRNA transfection into 
viable CD3+ T cells. 
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Figure 3.11 A 2:1 ratio of siRNA (µg):Lipofectamine 2000 (µL) provides the optimal 
T cell transfection efficiency and total viability. 2 million lymphocytes from the lymph 
nodes of WT C57BL/6 were plated in a 24 well plate and transfected with 1 µg/mL of 
GAPDH-Cy3 siRNA while varying the amounts of Lipofectamine 2000. 48 hours after 
transfection cells were stained with Viability Dye eFluor 506 and CD3-FITC. Flow 
cytometric analysis was performed to determine the (A) transfection efficiency by 
measuring Cy3 fluorescence in viable CD3+ T cells and (B) total viability by gating on 
CD3+ T cells. The data shown are representative of three independent experiments. 
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real time RT-qPCR. The data showed that using the GAPDH siRNA, gene expression 
was silenced approximately 75%, demonstrating the effectiveness of the T cell 
transfection protocol (Figure 3.12). 
 Since PD1 expression is low on naïve T cells (Figure 3.1B), a 4 day anti-CD3e 
treatment was used to induce PD1 expression and to determine if reduction of intrinsic 
miRNA could increase anti-CD3e stimulated PD1 expression. Two million lymphocytes, 
collected from the lymph nodes of WT C57BL/6 mice, were plated in a 24 well plate and 
transfected with miRNA inhibitors for 48 hours using a 2:1 ratio of siRNA:Lipofectamine 
2000 (µg:µL). After a 4 day exposure to anti-CD3e, cells were collected and stained for 
PD1, CD4, CD8 and viability. Compared to miRNA inhibitor control, anti-miR-28 and 
anti-miR-107 transfected CD4+ T cells demonstrated a 15.66% and 16.39% fold-increase, 
respectively (Figure 3.13A). CD8+ T cells displayed a similar trend with 27.38%, 26.15% 
and 33.77% fold-increase in miR-28, miR-150 and miR-107, respectively (Figure 3.13B). 
miR-103 transfection had no effect on PD1 expression in both CD4+ and CD8+ T cells 
(Figure 3.13A and B). 
 
3.8 miR-28 and miR-107 mimic transfection has no effect 
on proliferation in CD4+ T cells. 
To investigate the therapeutic potential of miR-28 and miR-107, lymphocytes were 
transfected with 1 µg of mimic control, miR-28 or miR-107 for 48 hours and stained with 
CFSE before a 4 day incubation on anti-CD3e coated plates (10 µg/mL). CD4+ T cells 
were isolated using MACS beads and PD1 expression was analyzed to determine if these 
miRNA mimics can silence PD1 in T cells in vitro. While miR-107 had no significant 
effect on PD1 expression, miR-28 mimic reduced PD1 expression from 80.3% to 70.9% 
(Figure 3.14). To investigate whether this silencing resulted in altered proliferation the 
CD4+ T cells were analyzed using flow cytometry with CFSE staining. By gating on 
CFSElow cells, the proportion of proliferating cells was analyzed between miRNA mimics 
and control (Figure 3.15A). No significant difference in the percent of proliferating cells 
was found between the control or miR-28/miR-107 mimic transfection (Figure 3.15B). 
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Figure 3.12 A 2:1 ratio of GAPDH siRNA (µg):Lipofectamine 2000 (µL) results in a 
75% knockdown in GAPDH expression 48 hours after transfection. Using 1 µg of 
GAPDH siRNA or control siRNA with a 2:1 ratio of siRNA:Lipofectamine 2000 
(µg:µL), 2 million lymphocytes isolated from the lymph nodes of WT C57BL/6 were 
transfected in a 24 well plate. 48 hours after transfection, T cells were purified and RNA 
was isolated for use in real time qPCR with oligomers for GAPDH and β-actin (reference 
gene). A one-way ANOVA and Dunnett’s multiple comparison test was used to compare 
the control and GAPDH siRNA to the non-transfected cells (* = p <0.05). Data are 
representative of four independent experiments. 
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Figure 3.13 miR-28, miR-150 and miR-107 inhibitors increase PD1 expression after 
T cell transfection and incubation on anti-CD3e coated plates. 2 million lymphocytes, 
collected from lymph nodes of WT C57BL/6 mice, were plated per well in a 24 well 
plate and transfected with 1 µg of miRNA inhibitor or inhibitor control. Cells were 
transfected at 37 °C for 48 hours before being transferred to a 24 well plate coated with 
10 µg/mL of anti-CD3e for 4 days. Flow cytometric analysis was performed to determine 
the miRNAs ability to alter expression of PD1 on (A) CD4+ and (B) CD8+ T cells. A one-
way ANOVA test was used to determine significance (p < 0.05), significance between 
the miRNA inhibitors and inhibitor control was determined with a Dunnett’s multiple 
comparison test. Bars marked with a ** denote p < 0.01 and *** denote p < 0.001. The 
data shown are representative of three independent experiments. 
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Figure 3.14 miR-28 significantly silences PD1 expression in CD4+ T cells after 
transfection and incubation on anti-CD3e coated plates. Lymphocytes were isolated 
from lymph nodes of WT C57BL/6 mice and 2 million cells were plated per well in a 24 
well plate. 1 µg of miRNA mimic or mimic control were transfected and cells were 
transfected at 37 °C for 48 hours before being transferred to a 24 well plate coated with 
10 µg/mL of anti-CD3e for 4 days. CD4+ T cells were isolated using MACS beads and 
flow cytometric analysis was performed to determine the miRNAs ability to silence 
expression of PD1 in T cells. Significance was determined using a one-way ANOVA 
followed by a Dunnett’s multiple comparison test between control and each miRNA 
mimic (*** = p < 0.001). Data are representative of two independent experiments. 
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Figure 3.15 miR-28 and miR-107 have no effect on cell proliferation induced by 
anti-CD3e stimulation. 2 million lymphocytes, isolated from lymph nodes of WT 
C57BL/6 mice, were plated per well in a 24 well plate. 1 µg of miRNA mimic or mimic 
control were transfected and cells were transfected at 37 °C for 48 hours. Cells were then 
stained with CFSE then plated on anti-CD3e coated plates (10 µg/mL) for 4 days before 
CD4+ T cell isolation, PD1-PerCP eFluor710 staining and flow cytometric analysis. (A) 4 
day CFSE histogram showing the proliferation profiles of mimic control, miR-28 and 
miR-107 transfected T cells. (B) Quantification of the percentage of proliferated T cells 
(CFSElow). Significance (p < 0.05) was determined using a one-way ANOVA followed 
by a Tukey’s post-hoc test. Data shown are representative of four independent 
experiments. 
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3.9 miR-28 mimic transfection reduces anti-CD3e induced 
early and late apoptosis in CD4+ T cells 
The last experiment was designed to determine if transfection of CD4+ T cells with 
miRNA mimic could reduce apoptosis in activated T cells. Lymphocytes were transfected 
as described in 3.8, however, no cells were stained with CFSE before 4 day incubation on 
anti-CD3e coated plates. After incubation, CD4+ T cells were isolated and stained for 
PD1, Viability Dye eFluor 506 and Annexin V-FITC. Cells that stain eFluor506-
AnnexinV+ are in early apoptosis, while cells that stain eFluor506+AnnexinV+ are in late 
apoptosis. miR-107 transfection had a significantly increased percentage of viable CD4+ 
T cells (15.13% > 4.22%) and decreased percentage of late apoptotic cells (68.73% < 
81.87%) over control (Figure 3.16A and B). miR-28 transfected CD4+ T cells displayed 
even greater reductions in apoptosis compared to control: viability increased from 4.22% 
to 29.83%, early apoptosis decreased from 12.07% to 5.62% and late apoptosis decreased 
from 81.87% to 61.37% (Figure 3.16A and B). 
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Figure 3.16 miR-28 mimic transfection significantly reduces the percentage of cells 
in early and late apoptosis caused by prolonged anti-CD3e activation. Lymphocytes 
were isolated from lymph nodes of WT C57BL/6 mice and 2 million T cells were plated 
per well in a 24 well plate. 1 µg of miRNA mimic or mimic control were transfected and 
cells were cultured at 37 °C for 48 hours before being plated on anti-CD3e coated plates 
(10 µg/mL) for 4 days. Using CD4 MACS beads, CD4+ T cells ere purified and stained 
with PD1-PerCP eFluor710, viability dye eFluor 506 and annexin V FITC and analyzed 
by flow cytometry. (A) Dot plot showing viable (eFluor506-annexinV-), early apoptotic 
(eFluor506-annexinV+) and late apoptotic (eFluor506+annexinV+) CD4+ T cells after 
transfection with mimic control, miR-28 or miR-107 and 4 day treatment with anti-CD3e. 
(B) Quantification of the viable, early and late apoptotic CD4+ T cells. Within each stage 
of apoptosis, the miRNA mimics and controls were compared using a one-way ANOVA 
followed by Tukey’s post-hoc test (* = p < 0.05, ** = p < 0.01 and *** = p < 0.001). 
Data are representative of three independent experiments. 
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Chapter 4  
4 Discussion 
4.1 Discussion 
The key findings from this study are: 1) miR-28, miR-150 and miR-151-5p are 
downregulated; and miR-let-7e, miR-103, miR-107, miR-27a, miR-23a, miR-21, miR-
155 and miR-146a are upregulated in PD1+CD4+ T cells, 2) in silico data reveal that miR-
28 and miR-150 should bind to the 3’ UTRs of PD1, TIM3 and BTLA, while miR-103 
and miR-107 bind to PD1 and BTLA, 3) anti-CD3e treatment upregulates PD1 
expression and decreases expression of all 4 candidate miRNAs, 4) miR-28 and miR-107 
bind to the 3’ UTR of PD1 and silence PD1 expression, while lymphocyte transfection 
with miR-28, miR-150 and miR-107 inhibitors increase PD1 expression on T cells and 5) 
although no differences in proliferation were seen in miRNA mimic transfected CD4+ T 
cells, miR-28 and miR-107 transfection lead to reduced early and late activation-induced 
apoptosis.  
 miRNAs are quietly emerging as new therapeutic markers for use in various 
diseases. Currently, two miRNA based therapeutics are in clinical trials that use a LNA 
anti-miR-122, miravirsen, against hepatitis C [106] or liposome-based miR-34a mimic, 
MRX34, against a multitude of cancers [107]. Although it is exciting to see the 
emergence of a new class of drugs for use in cancer therapy, miRNAs have their 
limitations. Although a miRNA may be able to target multiple genes in pro-tumoral 
pathways to elicit a broad anti-tumor responses, the possibility also exists for negative 
off-target effects [108]. As well, a miRNA may have separate targets in different cell 
types, i.e. cancer vs an immune cell, which can be beneficial or harmful as a therapeutic 
approach.  
One of the most important factors that contribute top success of RNAi therapies is 
the ability to deliver small RNA molecules inside the cell. A high transfection efficiency 
is necessary to ensure that the RNA has a significant effect on cell function, while a low 
toxicity is important to ensure that the therapeutic benefits of gene silencing outweigh the 
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cell loss due to transfection. T cells are difficult to transfect, and currently the most 
popular method to transfect primary human and murine T cells with siRNA/miRNA in 
vitro is electroporation. Electroporation uses an electric field to disrupt the cell membrane 
and allow RNA to enter the cell [109]. The industrial leader in T cell electroporation is 
Lonza with the Lonza Nucleofector II electroporation system and Amaxa Nucleofector 
Kits. When comparing homemade buffers to the ones found in the Amaxa Nucleofector 
Kit for human and murine T cells, Chicaybam et al. discovered that the Amaxa kit was 
superior at transfecting human T cells with approximately 45% transfection efficiency 
and 70% viability. On the other hand, the homemade buffer was superior at transfecting 
murine T cells with the transfection efficiency and viability at 40% and 60%, respectively 
[110]. In this study, a 2:1 ratio of siRNA (µg):Lipofectamine 2000 (µL) resulted in a 
greater murine T cell transfection efficiency of 62.7% and reduced total viability of 
29.8% when compared to the Amaxa or homemade electroporation kits (Figure 3.11). 
Overall, the lipofectamine protocol may prove more versatile since electroporation is 
limited to transfecting activated T cells only; non-activated T cells demonstrated below 
10% transfection efficiency and viability [110]. Other mentionable factors that lead to 
increased viability were the addition of 2-ME, a reducing agent that prevents oxygen 
radical buildup, and absence of penicillin or streptomycin in the transfection medium as 
per manufacturer’s instructions. 
Another issue that arose in this study was naturally low expression of PD1 on T 
cells from WT C57BL/6 mice. In order to demonstrate silencing of PD1, and how that 
affects the function of CD4+ T cells, PD1 expression needed to be induced. One study 
conducted by Park et al. generated γ-retroviral vectors for expression of artificial 
miRNAs and transfected the vector into human lymphocytes along with one for 
constitutive expression of PD1 [111]. Of importance, miR-150 was able to silence vector-
induced PD1 expression by approximately 90% 5 days after lymphocyte culture. It must 
be kept in mind, however, that the artificial vectors were created by designing a hybrid 
RNA molecule that resembles the endogenous miRNA with the stem sequence replaced 
by a siRNA against PD1. Consequently, the large silencing effect seen may be over-
exaggerated by the presence of PD1 siRNA. As well, since human T cells were used for 
transduction and the analysis was conducted using flow cytometry, it is unknown whether 
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the miR-150 directly bound the PD1 transcript or indirectly silenced PD1. Therefore, this 
research project is the first to demonstrate that not only do miR-28 and miR-107 directly 
regulate PD1 expression through its 3’ UTR, but miR-150 also indirectly silences PD1 in 
T cells through some unknown pathway. In order to avoid T cell transfection with 
miRNAs and a large vector, it was decided to use other means to induce PD1 expression. 
Anti-CD3e was chosen based on previous research that successfully used anti-CD3e to 
induced PD1 expression and T cell anergy on CD4+ T cells to test the therapeutic effects 
of PD1 siRNA [29]. IFNγ was tested based on curiosity since it can induce PD-L1 
expression on B16 melanoma cells and other cancers [112-114]. 
In the past decade miRNA research has exploded and been explored as diagnostic, 
prognostic and therapeutic makers, but to date very little miRNA research exists on PD1, 
and none exist sin the scope of melanoma therapy. One of the first miRNA and PD1 
papers, written by Iliopoulos et al., discovered that miR-21 was significantly upregulated 
upon ovalbumin stimulation in T cells, and that inhibition of PD1 with siRNA or 
knockout mice increased miR-21 expression [115]. As well, that miR-21 was found to 
control PDCD4, an intracellular protein with similar inhibitory effects as PD1 [115]. 
Recent studies on miR-21 and T cell activation demonstrate increased miR-21 expression 
in active or differentiated T cells [116, 117]. In this study, miR-21 was increased 10-fold 
in PD1+CD4+ T cells, which is comparable to the miR-21 expression before and after 
ovalbumin stimulation. This paints the picture that tumor-specific T cells in the tumor 
microenvironment would activate, upregulate miR-21 and PD1, which results in PD1 
silencing miR-21 and inducing the tumor suppressor targets of miR-21: PDCD4, PTEN 
and Bcl-2 [118]. In terms of T cell exhaustion, high miR-21 expression is considered 
therapeutic as it prevents upregulation of suppressor genes in the T cells; however, for 
many different cancers cells miR-21 is considered an oncomir as it supports continued 
cell growth. Therefore, if miRNA hope to have a place in immunotherapy then cell 
specific delivery techniques need to be in place to ensure removal of immune suppression 
in T cells while preventing miR-21-induced tumor-suppressor silencing in cancer cells. 
Moreover, it seems that miR-21 has altered regulating roles depending on the 
differentiation status of the CD4+ T cell. Memory T cells have miR-21 function anti-
apoptotically, while miR-21 in newly activated T cells silence CCR7 and modulates 
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lymphoid organ migration [119]. Therefore, specific delivery of miRNA into T cells may 
also be limited by specific subset delivery. 
Other miRNAs of relevance in cancer immunotherapy are miR-150, miR-155 and 
miR146a. In this study, miR-150 expression was significantly decreased in PD1+ T cells 
and shown to indirectly regulate PD1 expression. miR-150 mimic displayed no direct 
silencing of the 3’ UTR of PD1 in the dual luciferase assay, but miR-150 inhibitors 
increased PD1 expression in T cells. Other studies reveal that miR-150 is downregulated 
in T cell lymphoma and colorectal cancer and is a tumor suppressor by targeting c-Myb 
[57, 120]. Conversely, in bladder cancer miR-150 is upregulated which results in lower 
PDCD4 expression [121]. Thus, miR-150 can be seen as a double edge sword as it acts as 
a tumor suppressor by silencing the oncogene c-Myb, while at the same time acting as an 
oncomir by silencing PDCD4 and increasing cell invasiveness. Overall, this strengthens 
the idea that miRNA regulation can be specific for different cell types and disease states, 
and therefore results from other studies on miRNAs and cancer may not necessarily 
translate to the field of melanoma immunotherapy. 
miR-155 and miR-146a were the most altered in PD1+ cells with approximately 
12 and 21 fold increase, respectively. miR-155 is an interesting miRNA as it has been 
shown to silence CTLA4 [122], and miR-155 knockout mice are highly resistant to 
autoimmunity, which is reversed in miR-155(-/-)Pdcd1(-/-) double knockout mice [123]. 
Upon T cell activation miR-155 has been shown to increase in expression and silence 
suppressor of cytokine signaling 1 (SOCS1) [124]. Thus, miR-155 is normally induced 
upon activated T cells and has two silencing pathways to support cell proliferation and 
maturation. miR-146a is normally low in naïve human T cells and is induced upon T cell 
receptor stimulation [125, 126]. Moreover, miR-146a expression is correlated to 
decreases in activation-induced cell death by targeting fas-associated death domain 
(FADD) [125]. However, similar to miR-150, miR-146a acts as a double edge sword to T 
cell growth and survival by targeting and silencing IL-2 through IRAK1 and TRAF6 
[125] and inhibiting NF-κB activity, thus preventing hyperactivity in antigenic responses 
[126].  
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miR-23a recently has become a popular regulator of cytoxicity in CD8+ T cells. 
TGF-β derived from tumors tissue upregulates miR-23a in CD8+ T cells resulting in 
silencing of BLIMP-1, a promoter of cytotoxicity. From this discovery an effective 
adoptive cell therapy was created in mice by transfecting tumor-specific CD8+ T cells 
with miR-23a inhibitor, resulting in reduced tumor growth [127]. Another study on miR-
23a in CD8+ T cells also found that increased miR-23a expression induced attenuation of 
cytotoxicity, which may be due to silencing of lysosomal-associated membrane protein 1 
(LAMP1) [128]. In the same study, miR-27a was shown to directly silence IFNγ acting as 
a partner to miR-23a to lower cytotoxicity upon TGF-β stimulation. Although increases 
in miR-23a and miR-27a expression were observed in CD4+PD1+ T cells, it is difficult to 
tell if miR-23a and miR-27a exhibit suppressive functions in CD4+ T cells. Studies so far 
have only looked at miR-23a and miR-27a in CD8+ T cells by investigating changes in 
cytotoxicity, and therefore no data is available to confirm if these miRNAs affect CD4+ T 
cell function. 
The previously mentioned miRNAs have been studied extensively in T cells and 
in cancer, and they demonstrate the delicate nature of a miRNA therapy in T cells. Due to 
the dual and opposite functions that miRNA can elicit, some miRNAs may have 
undesired off-target effects that can reduce the therapeutic benefits of miRNA regulation. 
Moreover, miRNAs can alter function depending on the cell-type transfected, thus 
efficient targeted delivery may be mandatory in order to observe functional changes or 
reduce off-target effects. Moving forward, the aim of this research was to discover 
miRNA that silence PD1 expression, which is why miR-28, miR-150, miR-103 and miR-
107 were chosen for further study. 
To date, almost no papers exist that focus on the function of miR-103 and miR-
107 in T cells. One study, although focused on triple-negative breast cancer, analyzed the 
prognostic performance of miRNAs in 58 patients and found that lymph node status was 
the only clinicopathological factors that was significant in predicting poor prognosis. As 
well, that poor prognosis and distant metastasis were correlated to high intratumoral miR-
103 and miR-107 expression [129]. Other research groups compared serum miRNA 
levels between breast cancer and healthy patients, and found elevated miR-107 levels 
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[130, 131].  Similar results were seen in lung and pancreatic cancer, where miR-107 was 
associated with tumor growth and decreased lung cancer survival and miR-103 was 
associated with risk of pancreatic cancer, however, miR-107 and miR-103 were lower in 
cancerous tissue [132, 133]. The prognostic potential of these miRNAs is not limited to 
disease progression, but extends towards therapeutic outcome prediction. Another study 
aimed to detect if miRNA levels can be used to predict outcomes of chemotherapy. 
Patients with metastatic colorectal cancer were treated with chemotherapy and 
intratumoral miRNA levels were measured. It was discovered that high miR-107 
correlated to overall survival [134]. Plenty of evidence exists to confirm the prognostic 
potential of miR-103 and miR-107, however it appears expression changes seem to differ 
depending on the disease. This may be due to the fact that, similar to miR-150 and miR-
146a, both miR-103 and miR-107 can act as oncomirs or tumor suppressive miRNAs by 
targeting DICER, PTEN or CCND1, CDK8, MCL1, PD1 respectively [134-137]. In this 
study, miR-103 and miR-107 was approximately 3-fold increased in PD1+CD4+ T cells 
over PD1-CD4+ T cells isolated from tumor-bearing mice, however, when CD4+ T cells 
are stimulated with anti-CD3e for 24 hours expression of miR-103 and miR-107 
decreased. Therefore, the increased miR-103 and miR-107 expression observed in PD1+ 
cells may either be a result of the presence of melanoma or a marker of exhausted T cells. 
miR-28 became the candidate miRNA that fulfilled the objectives of this study. 
Reductions were seen in PD1+CD4+ T cells, miR-28 was shown to silence the 3’ UTR of 
PD1 and use of miR-28 mimic and inhibitors altered PD1 expression resulting in the most 
significant decrease in activation-induced cell death. Current research involving miR-28 
and T cell disease primarily focuses on HIV infection, but one research article on natural 
killer/T-cell lymphoma (NKTL) demonstrated reductions in miR-28 expression in 
cancerous cells. However, transfection with miR-28 mimic reduced cell growth in NKTL 
cells [138]. When looking at a different immune cell, the B cell, miR-28 expression is 
reduced in B cell lymphoma and reexpression of this miRNA leads to impaired cell 
proliferation through MAD2L1, a component of the cell cycle through mitotic spindle 
coordination [139]. With focus on a non-immune cell related cancer, clear cell renal cell 
carcinoma, miR-28 mimic transfection was shown to weaken mitotic checkpoint 
activation and induce chromosomal instability by also targeting MAD2L1 [140]. 
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Although miR-28 reexpression in my study proved beneficial to CD4+ T cells, these 
contradicting results illustrate the necessity to further understand altered miRNA 
expression between subsets of T cells (CD4+ vs CD8+ or NK cells), as well as between 
whether the T cell is the origin of the disease or merely a combatant in the fight against 
cancer. In the end, the fact cannot be ignored that miR-28 is downregulated in a multitude 
of cancerous immune cells and tissues, and maintains a tumor suppressive role by 
reducing growth of cancerous cells through MAD2L1. This research project expands the 
role of miR-28 as an indirect tumor suppressor by preventing cell death in activated CD4+ 
T cells through silenced PD1 expression. 
  In conclusion, miR-28 and miR-107 were shown to silence PD1 through its 3’ 
UTR, and transfection with miR-28 and miR-107 mimics reduced early and late 
activation-induced cell death. Therefore, miR-28 and miR-107 remain as great candidates 
to act as a silencing therapeutic agent against PD1. Ultimately, this novel research 
demonstrates a potential role for miR-28 and miR-107 in regulating T cell responses to 
cancer. With the success that anti-PD1 antibodies are having in clinical trials, 
investigating how miRNA regulates PD1 in T cells is necessary to expand our 
understanding of immunoregulatory pathways for prognostic and therapeutic purposes. 
 
4.2 Future Directions 
In this thesis, the microarray profile between PD1+/- CD4+ T cell allowed us to discover, 
for the first time, miRNAs from a murine melanoma model that alter expression based on 
PD1 status. With a focus towards reversing T cell suppression caused by melanoma, 
various miRNAs were highlighted as candidates to silence PD1 and other T cell 
exhaustion markers. However, more can be done to further understand how miR-28 and 
miR-107 regulate T cell function in vitro. For instance, an ELISA or intracellular flow 
cytometry staining of IFNγ, TNFα and IL-2 after miRNA mimic/inhibitor transfection is 
recommended to determine if these miRNA can increase anti-tumoral cytokine secretion. 
Moreover, to understand how miR-28 and miR-107 affect CD8-mediated cytotoxicity, a 
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cytotoxic T lymphocyte killing assay can be performed using miRNA-transfected CD8+ 
T cells and labelled B16F10 cells. 
In order to determine if any of the candidate miRNA affect TIM3 or BTLA 
expression, the pmirGLO dual luciferase assay should be utilized in tandem with miRNA 
mimic/inhibitor transfection of T cells. The dual luciferase assay displays miRNAs that 
directly bind to the 3’ UTR, while in vitro T cell transfection provides a more 
physiological relevant microenvironment to confirm direct and indirect expression 
changes. 
The final step for this study would involve a translation to in vivo murine 
melanoma model to discover if these miRNAs can improve T cell function against 
B16F10 melanoma. Evidence has shown that miRNAs may have opposing functions in 
different cell types, therefore a T cell specific delivery system is necessary to minimize 
the off-target effects of the miRNA candidates. Many new methods are coming to fruition 
by using CD7 antibody conjugated to oligo-9-arginine (scFvCD7-9R), CD7 antibody 
conjugated to chitosan or RNA-secreting primary B lymphocytes to deliver RNA into T 
cells [124, 141-143]. Alternatively, to avoid the barrier of specific T cell gene delivery in 
vivo, current in vitro methods can be used to transfect T cells for adoptive cell transfer. If 
altering expression of miRNAs, such as miR-28 and miR-107, in T cells can demonstrate 
control of T cell function towards melanoma in a mouse model, it would warrant 
translation to human T lymphocytes from melanoma patients.  
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